In preclinical studies, we demonstrated that combination treatment with lovastatin and EGFR-TKIs at concentrations between 1 and 10 μM induced synergistic cytotoxicity in SCC, NSCLC and colon cancer cell lines [27, 28]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.